Precigen Inc Stock Price, News & Analysis

Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari will participate in two key conferences. She will engage in a virtual fireside chat at the Wells Fargo Virtual Healthcare Conference on September 9, 2021, at 8:40 AM ET. Additionally, she will present at the H.C. Wainwright 23rd Annual Global Investment Conference, with the webcast available on-demand starting September 13, 2021, at 7:00 AM ET. Webcast access is available via Precigen's website.

Precigen, Inc. (Nasdaq: PGEN) reported its second quarter and first half 2021 financial results, highlighting a total revenue increase of 10% year-over-year for Q2. However, net loss from continuing operations was $20.1 million, equivalent to $(0.10) per share. The company is advancing its clinical pipeline, with ongoing trials for PRGN-3005 and PRGN-3006 UltraCAR-T therapies and PRGN-2009 AdenoVerse immunotherapy. Precigen anticipates interim data presentations in Q4 2021, indicating a pivotal year for its innovative therapies.

Precigen, a biopharmaceutical company focused on gene and cell therapies, will release its second quarter and first half 2021 financial results after market close on August 9, 2021. A conference call will be held at 4:05 PM ET on the same day to discuss the results and provide a business update. Investors can access the call by dialing specific numbers or register through the company's website. Precigen emphasizes its commitment to innovative therapies targeting critical diseases, enhancing its pipeline direction toward clinical proof-of-concept.

Precigen ActoBio announced positive topline results from its ongoing Phase 1b/2a clinical study of AG019 ActoBiotics for treating recent-onset type 1 diabetes (T1D). The treatment targets autoimmune responses by delivering human proinsulin and interleukin-10 to induce regulatory T cells. Results show that 56% of adult patients receiving AG019 monotherapy stabilized or increased C-peptide levels. In combination therapy with teplizumab, 70% of adults and 100% of adolescents had similar results. The therapy appears safe, with no serious adverse events reported, paving the way for future studies.

Precigen, Inc. (Nasdaq: PGEN) announced that Dr. Helen Sabzevari, President and CEO, will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 17, 2021, at 11:00 AM ET. The event will be accessible through Precigen's website in the Events & Presentations section. The company focuses on innovative gene and cell therapies targeting urgent diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen aims to advance affordable biotherapeutics and has a robust pipeline moving toward clinical proof-of-concept.

Precigen, Inc. (Nasdaq: PGEN) reported its Q1 2021 financial results, highlighting significant advancements in its clinical trials. The UltraCAR-T therapies, PRGN-3005 and PRGN-3006, showcased promising safety profiles and clinical activities, with ongoing dose escalation phases. The company initiated the PRGN-2012 study, received orphan drug designations for multiple therapies, and anticipates upcoming data presentations. Financially, total revenues fell by 18% to $24.5 million, attributed mainly to decreased collaboration revenues. However, total cash on hand stands at $209.3 million.

Precigen, a biopharmaceutical company, announced that Chief Financial Officer Rick Sterling will step down effective April 2, 2021, by mutual agreement. The company is actively seeking a qualified successor to support its transition from a clinical-stage to a commercial organization. CEO Helen Sabzevari highlighted the importance of this role in maintaining growth momentum and preparing for commercial readiness of their lead products. Precigen specializes in gene and cell therapies aimed at addressing urgent diseases, particularly in immuno-oncology and autoimmune disorders.

On March 23, 2021, Precigen announced that the first patient has been dosed in a Phase I study of PRGN-2012, an off-the-shelf immunotherapy targeting recurrent respiratory papillomatosis (RRP). Recently granted Orphan Drug Designation by the FDA, PRGN-2012 utilizes gorilla adenovector technology to generate immune responses against HPV 6 and HPV 11. The trial aims to assess the safety and tolerability of PRGN-2012, involving up to 12 patients at maximum tolerated doses. This milestone could provide RRP patients with new therapeutic options, reducing the need for repeat surgeries.

Precigen, a biopharmaceutical company, announced that the FDA granted orphan drug designation for its investigational immunotherapy PRGN-2012, aimed at treating recurrent respiratory papillomatosis (RRP). This designation provides access to various incentives that may expedite development and commercialization. PRGN-2012, developed in collaboration with the National Cancer Institute, utilizes gorilla adenovector technology to prompt immune responses against HPV 6 and 11. The condition affects a small population, making novel treatments critically needed. CEO Helen Sabzevari emphasized the urgency for new therapies.